MEDICAL MARIJUANA, INC. INVESTMENT AXIM® BIOTECHNOLOGIES, INC. SECURES FUNDING TO CONTINUE PHARMA CLINICAL TRIALS PROGRAM IN CANNABINOID R&D
Financing Enables Cannabinoid Innovator to Continue Phase I-II Trials Of Numerous Intellectual Property (IP) Protected Cannabinoid-Based Products for Multiple IndicationsMedical Marijuana, Inc. (OTC: MJNA) today announced that its portfolio company AXIM® Biotechnologies, Inc. (AXIM® Biotech ) (OTC: AXIM), a world leader in cannabinoid research and development, has secured private funding to continue its pharmaceutical clinical trials program in cannabinoid research and development for multiple indications. AXIM® Biotech’s most